Most Discussed Stocks
25 Feb 2009
Elan
Corporation, plc is a neuroscience-based biotechnology company that is focused
on discovering, developing, manufacturing and marketing advanced therapies in
neurology, autoimmune diseases, and severe pain.
On June 5,
2006, Elan and Biogen Idec announced the approval of a supplemental Biologics
License Application (sBLA) by the U.S. Food and Drug…
09 Feb 2009
Savient Pharmaceuticals, Inc. is a
biopharmaceutical company engaged in developing and distributing pharmaceutical
products. The firm's product development candidate, pegloticase for treatment-failure
gout, has reported positive Phase 1, 2 and 3 clinical data. Patient dosing in
the Phase 3 clinical studies began in June 2006; patient enrollment was completed
in…
04 Feb 2009
Cytokinetics discovers,
develops and commercializes novel small molecule
drugs for Cardiovascular diseases: The program focuses on cardiac myosin,
a motor
protein essential to cardiac muscle contraction. Cytokinetics'
lead
compound from this program, CK-1827452, a novel small molecule
cardiac
myosin activator, entered Phase 2 clinical trials for the
treatment of
heart…
28 Dec 2008
AAIPHARMA is a service organization
that emerged from chapter 11 bankruptcy protection and is on its way to
rebuilding. AAI Pharma provides pharmacetuical outsourcing services to
the pharmaceutical, biotech, and medical device industries. Currently, the firm
is focusing also on drug development and support operations. The firm sold a unit…
18 Aug 2008
Dyax’s
discovers, develops and commercialize innovative biopharmaceuticals for unmet
medical needs. Dyax’ therapeutic product candidates include fully human
monoclonal antibodies as well as small proteins and peptides. Dyax
focuses on oncology and inflammation. Its discovery technology provides it with
the capability of identifying and developing its own clinical leads.
The…
